Enhertu PopPK
Indication: HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
Interactive population pharmacokinetics simulator for trastuzumab deruxtecan (T-DXd / ENHERTU). Sequential 2-compartment ADC and 1-compartment released DXd payload model. Covariate effects on CL and volume. Based on Yin et al. Clin Pharmacol Ther 2021.
Drug Overview
Clinical Context
- Molecular Target
- HER2
- Drug Class
- Antibody-Drug Conjugate (ADC)
- Therapeutic Area
- Oncology
- Indication
- HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
- Route of Administration
- IV Infusion
Model Information
- Model Type
- Population PK (Sequential 2-CMT ADC + 1-CMT Payload)
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Enhertu allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK (Sequential 2-CMT ADC + 1-CMT Payload) model characterizes the pharmacokinetics of this antibody-drug conjugate (adc) following iv infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Enhertu PK simulator?
This is a free, interactive pharmacokinetic simulator for Enhertu used in HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Enhertu belong to?
Enhertu is classified as a Antibody-Drug Conjugate (ADC) that targets HER2. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV Infusion administration of Enhertu. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK (Sequential 2-CMT ADC + 1-CMT Payload) model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
PopPK of Docetaxel
Mirvetuximab Soravtansine (ELAHERE) PopPK
FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
Patritumab Deruxtecan (HER3-DXd) PopPK
EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload
capecitabine
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Ready to Simulate?
Launch the Enhertu simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community